Chronic Hepatitis

Etiology and Risk Factors

Cause	Disease mechanism / distinguishing feature	Diagnostic direction
Chronic hepatitis B (± D)	Persistent viral infection and immune-mediated injury; HBV may increase hepatocellular carcinoma risk even without cirrhosis. HDV requires HBV and can worsen disease.	HBsAg status, HBV DNA and relevant HBe markers; stage fibrosis and assess HDV when appropriate.
Chronic hepatitis C	Persistent HCV RNA-associated inflammation; progression varies. Successful antiviral therapy can cure the infection, although advanced fibrosis risk persists.	Confirm active infection with HCV RNA; stage fibrosis; assess coinfection and prior treatment.
Autoimmune hepatitis	Loss of immune tolerance produces portal/interface hepatitis, commonly with elevated IgG and characteristic autoantibodies, but no single diagnostic test is definitive.	IgG, ANA/SMA and other relevant serology; review drugs, viral causes and histology when necessary.
Alcohol-associated liver disease	Repeated toxic, oxidative, metabolic and inflammatory injury may progress from steatosis to steatohepatitis and fibrosis.	Quantify exposure, nutritional status and comorbidity; assess for alcohol-associated hepatitis or cirrhosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD)	Metabolic dysfunction and hepatocyte lipid accumulation can provoke lipotoxicity, inflammation and progressive fibrosis in some patients. Older texts use NAFLD/NASH.	Assess diabetes, adiposity, lipid abnormalities, insulin resistance and noninvasive fibrosis risk.
Inherited, drug-associated or cholestatic disease	Examples include hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, chronic medication injury and PBC/PSC-associated cholangiopathy.	Iron studies, ceruloplasmin or genetic/enzyme testing, complete drug history, cholestatic markers/antibodies and bile-duct imaging as indicated.

Epidemiology and Clinical Context

Population context: HBV acquired around birth is substantially more likely to become chronic than HBV acquired in adulthood. HCV transmission risk is shaped by blood exposures, while metabolic risk, alcohol exposure, autoimmune disease, and inherited disorders change the differential for persistent liver injury (Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Pathophysiology

Progressive injury: from inflammation to fibrosis

Persistent viral antigens, immune dysregulation, metabolic lipotoxicity or recurrent toxic injury stimulate hepatocytes, Kupffer cells and other inflammatory pathways. Cytokines activate hepatic stellate cells, which transform into extracellular-matrix-producing myofibroblast-like cells. Progressive collagen deposition in the space of Disse diminishes sinusoidal exchange; bridging fibrosis can distort the vascular architecture and eventually produce regenerative nodules and cirrhosis. Etiologic treatment may slow or partially reverse fibrosis, but established decompensation carries additional risks (Mukhtar & Khalili, 2019).

Clinical Manifestations

Early chronic hepatitis may be detected only through abnormal liver tests or screening. When symptomatic, fatigue, anorexia, mild right upper quadrant discomfort, intermittent jaundice and hepatomegaly are possible. Spider angiomas, palmar erythema, splenomegaly, edema, ascites, encephalopathy or variceal bleeding suggest advanced disease and require assessment for cirrhosis and portal hypertension. Extrahepatic disease can arise with viral and autoimmune etiologies (Mukhtar & Khalili, 2019).

Diagnostic Evaluation

Use viral activity, fibrosis and functional reserve as independent assessments

For HBV, interpret the core serologic panel (HBsAg, anti-HBs, total anti-HBc) with HBV DNA, ALT and clinical context; HBeAg status may help characterize replication but cannot substitute for direct viral-load measurement. HBsAg persistence establishes chronic HBV, but decisions about antiviral therapy depend on virologic activity, injury, fibrosis, coinfections and patient-level risk rather than a single ALT. For HCV, a reactive antibody alone does not confirm current infection: HCV RNA distinguishes active infection from cleared or treated infection. Early suspected infection or immunocompromise can affect antibody interpretation (Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

Fibrosis staging asks a different question from inflammatory activity. Noninvasive tests such as FIB-4 and transient elastography can stratify risk, but age, platelet count, acute inflammation, cholestasis and test-specific limits can distort interpretation; discordant findings may require additional testing or biopsy. Persistently mild or normal enzymes do not rule out substantial fibrosis. Albumin, INR, platelet count, imaging and clinical decompensation give additional information about reserve and portal hypertension.

Interpret hepatitis B markers as patterns

The screening triple panel is HBsAg, anti-HBs, and total anti-HBc. Resolve an indeterminate pattern with exposure history, repeat or targeted serology, and HBV DNA when indicated. IgM anti-HBc supports recent acute infection but can also appear during severe flares of chronic HBV; no single test substitutes for clinical context (Conners et al., 2023; Mukhtar & Khalili, 2019; Williams & Gordon-Walker, 2023).

HBsAg / anti-HBs / total anti-HBc	Most likely interpretation	Next question
− / − / −	No evidence of current or previous HBV infection or vaccine response	Assess vaccination status, exposure recency and vaccine indication.
− / + / −	Vaccine-associated immunity	Anti-HBc remains negative after vaccination alone.
− / + / +	Resolved natural HBV infection	Assess reactivation risk if potent immunosuppression is planned.
+ / − / +	Current HBV infection; acute versus chronic remains unresolved	Use IgM anti-HBc, prior HBsAg history, HBV DNA and clinical course.
− / − / +	Isolated total anti-HBc; multiple explanations possible	Consider remote infection, false positive, window period or occult infection; use targeted follow-up.

HBeAg and anti-HBe help characterize replication patterns, but HBeAg-negative patients may still have active replication; HBV DNA, ALT, fibrosis and longitudinal trends determine the clinically meaningful state. Screen for both current and previous HBV before immunosuppression because reactivation may occur despite HBsAg negativity. Prevention may require specialist-directed antiviral prophylaxis or close surveillance according to agent-specific risk (Williams & Gordon-Walker, 2023).

For HCV, a reactive antibody documents prior exposure, not necessarily current infection; reflex HCV RNA testing determines whether viremia is present. If recent exposure is suspected, RNA may be indicated even with a nonreactive antibody. Undetectable HCV RNA at least 12 weeks after treatment (SVR12) is consistent with virologic cure; reinfection remains possible. Screen for hepatitis B, assess drug interactions and fibrosis before antiviral treatment, and continue cancer surveillance when cirrhosis remains an indication (American Association for the Study of Liver Diseases & Infectious Diseases Society of America, n.d.; Centers for Disease Control and Prevention, 2025).

Expected Findings

Clinical question	Measures	What they do not establish
Is inflammation or cholestasis active?	AST/ALT, ALP, bilirubin; etiology-specific inflammatory or viral markers.	Enzyme magnitude alone does not quantify fibrosis stage or reserve.
Has liver synthesis or excretion declined?	INR/PT, albumin, bilirubin; assess clinical context and alternative causes.	A normal albumin does not rule out early chronic disease; INR may be affected by anticoagulants.
Is fibrosis advanced?	Platelets, validated risk scores, elastography and liver imaging; histology when needed.	One normal ultrasound or low transaminase result does not exclude fibrosis.
What is driving the injury?	HBV/HCV tests, iron studies, autoimmune serology/IgG, metabolic review and targeted genetic studies.	A positive antibody test alone may not establish current active infection.
Has advanced disease developed?	Ascites, splenomegaly, varices, encephalopathy, HCC risk and other complications.	Compensated cirrhosis may precede overt clinical deterioration.

Differential Diagnosis

Terminology distinction: Chronic hepatitis is a pattern of persistent inflammatory injury, not a universal label for every chronic liver disorder. Metabolic steatotic liver disease and chronic cholangiopathies overlap the fibrosis differential but have distinct diagnostic frameworks. In the contemporary MASLD framework, hepatic steatosis with cardiometabolic risk factors is distinct from MASH, which involves hepatocellular ballooning and lobular inflammation; fibrosis staging determines the risk of advanced disease (European Association for the Study of the Liver et al., 2024).

Diagnostic Limitations and Reassessment

Histologic inflammatory grade indicates the current intensity of injury; fibrosis stage indicates how much structural damage has accumulated. Neither is synonymous with aminotransferase concentration. Normal or mildly elevated AST/ALT does not exclude advanced fibrosis; a symptom-free patient can still have clinically consequential liver disease.

Treatment and Management

• Hepatitis B: assess HBV DNA, ALT trends, HBeAg status, fibrosis, comorbidities and HCC risk before deciding on therapy. The AASLD/IDSA guideline (2026) supports shared decision-making for selected HBeAg-negative, HBsAg-positive noncirrhotic adults in an indeterminate phase; a single HBV DNA or ALT value is insufficient to apply every treatment threshold. Entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide are high-efficacy oral options, with renal, bone and pregnancy considerations affecting choice (Ghany et al., 2026).
• Hepatitis C: offer assessment for direct-acting antiviral treatment for active infection, with attention to interactions, HBV status and post-treatment viral RNA confirmation. Assess prior or current hepatic decompensation before selecting the regimen. AASLD–IDSA guidance advises against NS3 protease inhibitor-containing regimens (including glecaprevir, grazoprevir or voxilaprevir) in patients with prior or current decompensated cirrhosis or a Child–Turcotte–Pugh score of 7 or greater; these patients require specialist-directed regimen selection. Cirrhosis continues to require HCC surveillance after viral cure when the patient remains eligible; advanced fibrosis without cirrhosis requires guideline-specific risk assessment (American Association for the Study of Liver Diseases & Infectious Diseases Society of America, n.d.).
• Autoimmune hepatitis: specialist-directed immunosuppression may control inflammation; monitor response, relapse, adverse effects and fibrosis. Determine whether an alternative liver disease or overlapping cholangiopathy is present before treatment.
• Alcohol-associated and metabolic disease: address the underlying driver through sustained alcohol treatment/support when relevant, nutrition, cardiometabolic management and fibrosis risk reassessment. Counsel on vaccination where indicated and avoidance of unnecessary hepatotoxins.
• Across causes, monitor hepatic injury, synthetic function, fibrosis, medications, nutrition and clinical progression. For eligible patients, hepatocellular carcinoma surveillance commonly uses ultrasound plus alpha-fetoprotein about every six months; eligibility in chronic HBV without cirrhosis is risk-dependent and surveillance suitability depends on potential benefit from subsequent treatment (Singal et al., 2023).

Etiology-specific monitoring and cancer risk

Active HBV requires longitudinal assessment of DNA activity and liver injury; some patients retain hepatocellular carcinoma risk even without cirrhosis, depending on risk profile. Following HCV treatment, virologic cure is demonstrated by an appropriate post-treatment RNA result, but cirrhosis continues to warrant cancer surveillance after cure when the patient remains eligible; advanced fibrosis without cirrhosis requires guideline-specific risk assessment. Autoimmune hepatitis, metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated and cholestatic liver diseases have distinct treatment and monitoring goals; avoid applying viral-hepatitis thresholds to them.

Complications and Red Flags

Spider angiomas, palmar erythema, splenomegaly, edema, ascites, encephalopathy or variceal bleeding suggest advanced disease and require assessment for cirrhosis and portal hypertension (Mukhtar & Khalili, 2019).

Clinical Reasoning Priorities

A patient with chronic HCV has mild fatigue, ALT 46 U/L and a platelet count of 105,000/µL. The small ALT elevation does not establish mild disease. Thrombocytopenia raises concern for splenic sequestration from portal hypertension or another cause. Confirm HCV RNA, evaluate fibrosis with appropriate noninvasive methods, review hepatic synthetic function and assess for signs of advanced chronic liver disease. Treatment and surveillance planning must address both the infection and existing structural injury.

---

---

References

American Association for the Study of Liver Diseases & Infectious Diseases Society of America. (n.d.). Monitoring persons who are starting HCV treatment, are on treatment, or have completed antiviral therapy. HCV Guidance. Retrieved October 19, 2026, from https://www.hcvguidelines.org/guidance/monitoring-patients-who-are-starting-hcv-treatment-are-on-treatment-or-have-completed-therapy/

Centers for Disease Control and Prevention. (2025, January 31). Clinical screening and diagnosis for hepatitis C. https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/

Conners, E. E., Panagiotakopoulos, L., Hofmeister, M. G., Spradling, P. R., Hagan, L. M., Harris, A. M., Rogers-Brown, J. S., Wester, C., & Nelson, N. P. (2023). Screening and testing for hepatitis B virus infection: CDC recommendations—United States, 2023. MMWR Recommendations and Reports, 72(1), 1–25. https://doi.org/10.15585/mmwr.rr7201a1

European Association for the Study of the Liver, European Association for the Study of Diabetes, & European Association for the Study of Obesity. (2024). EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 81(3), 492–542. https://doi.org/10.1016/j.jhep.2024.04.031

Ghany, M. G., Pan, C. Q., Lok, A. S., Feld, J. J., Lim, J. K., Wang, S. H., Kim, A. Y., Tang, A. S., Nguyen, M. H., Naggie, S., Sulkowski, M. S., Rodriguez-Baez, N., Chen, J., Murad, M. H., Mohammad, K. S., & Terrault, N. A. (2026). AASLD/IDSA practice guideline on treatment of chronic hepatitis B. Hepatology, 83(4), 974–997. https://doi.org/10.1097/HEP.0000000000001549

Mukhtar, N. A., & Khalili, M. (2019). Liver disease. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed., Chapter 14). McGraw-Hill Education.

Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., Mendiratta-Lala, M., Brown, D. B., Rilling, W. S., Goyal, L., Wei, A. C., & Taddei, T. H. (2023). AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 78(6), 1922–1965. https://doi.org/10.1097/HEP.0000000000000466

Williams, M. J., & Gordon-Walker, T. T. (2023). Hepatology. In I. D. Penman, S. H. Ralston, M. W. J. Strachan, & R. P. Hobson (Eds.), Davidson’s principles and practice of medicine (24th ed., pp. 859–920). Elsevier.